Search Results for: New York medical marijuana

MedMen Acquires New York Medical Marijuana Company

CALIFORNIA: MedMen, a Los Angeles-based cannabis management and investment firm, announced today that it has acquired Bloomfield Industries, Inc., one of only five Registered Organizations licensed to operate a medical marijuana business in the State of New York. The acquisition provides MedMen with the opportunity to apply its operational expertise and institutional best practices to one of the largest potential medical marijuana markets in the country.

The transaction occurred through a sale of Bloomfield Industries’ capital stock, thereby allowing Bloomfield Industries to remain as the Registered Organization under the New York State Public Health Law.

Since October of 2016, MedMen has been working with Bloomfield Industries to help streamline operations, improve production capabilities and provide a better overall patient experience. MedMen’s post transaction plan includes the development of a state-of-the-art cultivation and production facility in Utica, as well as applying MedMen’s industry-leading retail model to Bloomfield’s current three pharmacies in Syracuse, Buffalo and Lake Success. Bloomfield Industries also intends to roll out a new pharmacy in Manhattan, making it one of only two medical marijuana pharmacies operating in the city.

“New York is critical to our broader strategy,” said Adam Bierman, co-founder and chief executive officer of MedMen. “We are talking about the fourth most populous state in the country and home to one of the largest, most densely populated cities in the world. We have the opportunity to serve roughly a fifth of that market, perhaps more and we are very excited about this opportunity.”

43 Companies Seeking New York Medical Marijuana Licenses

NEW YORK:  The race for one of New York’s medical marijuana licenses is underway. More than 40 different companies have laid out their plans for both growing facilities and distribution sites. WAMC’s Southern Adirondack Bureau Chief Lucas Willard has the latest on a handful of proposed businesses in our backyard.

Across the state, 43 different companies are hoping to secure one of New York’s medical marijuana licenses. Under the law signed last year, companies must both grow and distribute the drug through designated dispensaries. The drug cannot be smoked and the dispensaries cannot sell other pharmaceutical products.

Last week, Fiorello Pharmaceuticals announced its plans to open a grow facility in Glenville in Schenectady County.

 

New York Medical Marijuana, Out Of Joint

NEW YORK:  On Friday, New York became the 23rd state to pass a bill creating legal access to medical marijuana for patients with certain serious, debilitating conditions. Without question, this is a huge victory for New York patients with cancer, multiple sclerosis, epilepsy and other conditions who have been waiting many years for relief.

Still, the law leaves unchanged the unconscionable status quo in which tens of thousands of New Yorkers, most of them black and Latino, are put through the criminal justice system for mere possession of small amounts of marijuana.

And even within the context of medical marijuana, the legislation is the result of political compromises with the governor that were needed to gain final passage. Those compromises include serious limitations that will leave many patients behind and complicate implementation. It becomes clear that politics, not science, drove the final agreement.

New York Medical Marijuana Blinking Game Begins For Real

NEW YORK:  The sponsors of a bill legalizing medical marijuana made the midnight deadline to introduce a new version of the bill — the fifth — that bows to Gov. Andrew Cuomo on some of his ideas, but rejects a number of concerns he has publicly raised with the effort.

Sen. Diane Savino and Assemblyman Richard Gottfried amended their bill to, as Cuomo suggested, further limit the diseases or conditions for which the drug can be dispensed. Gone from the new bill is post-concussion syndrome, lupus and diabetes. But they keep intact the ability of patients to smoke the drug — Cuomo wanted an oil-based or other liquid type form of the drug being available — but the bill bans smoking in public places and, as previous versions, makes it illegal to dispense marijuana in a smoking form to anyone under age 21.

After Cuomo Monday characterized the lawmakers’ bill as overly generous when it comes to how much marijuana could go to patients in a 30-day period, Savino and Gottfried, in their new bill version, reduced from two and one-half ounces to two ounces the amount of marijuana that a doctor can prescribe to a patient in a one-month period. There appears also to be some new maneuvering room by the state health department, which will draft the regulations to implement the bill if it is passed and signed into law.

Lawmakers also did not go along with Cuomo’s call for a five-year sunset on the law. Savino and Gottfried both said that idea is unworkable and would serve to only keep private marijuana manufacturers from coming to New York to invest in the infrastructure to produce the drug.

Cuomo Said Set To Revive 1980 New York Medical Marijuana Law

NEW YORK:  Governor Andrew Cuomo is planning to revive a 1980 medical-marijuana law to allow some New York hospitals to make use of the drug for patients with cancer, glaucoma and other illnesses.

Cuomo, a Democrat, is expected to make the announcement in his Jan. 8 State of the State address, a person familiar with the speech said. The governor plans to use his executive authority to bypass the legislature where medical marijuana bills passed by the assembly have died in the Republican-controlled Senate. [Read more…]

Cuomo Said Set To Revive 1980 New York Medical Marijuana Law

NEW YORK:  Governor Andrew Cuomo is planning to revive a 1980 medical-marijuana law to allow some New York hospitals to make use of the drug for patients with cancer, glaucoma and other illnesses.

Cuomo, a Democrat, is expected to make the announcement in his Jan. 8 State of the State address, a person familiar with the speech said. The governor plans to use his executive authority to bypass the legislature where medical marijuana bills passed by the assembly have died in the Republican-controlled Senate. [Read more…]

New York State Department of Health Announces Opioid Replacement Now a Qualifying Condition for Medical Marijuana

Temporary ID Cards Will be Available for Certified Patients to Purchase Products More Quickly

NEW YORK:  The New York State Department of Health today announced the filing of emergency regulations adding any condition for which an opioid could be prescribed as a qualifying condition for medical marijuana.

Effective immediately, registered practitioners may certify patients to use medical marijuana as a replacement for opioids, provided that the precise underlying condition for which an opioid would otherwise be prescribed is stated on the patient’s certification. This allows patients with severe pain that doesn’t meet the definition of chronic pain to use medical marijuana as a replacement for opioids.

In addition, the regulation adds opioid use disorder as an associated condition. This allows patients with opioid use disorder who are enrolled in a certified treatment program to use medical marijuana as an opioid replacement.

Plans to add opioid replacement as a qualifying condition for medical marijuana were first announced last month.

“Medical marijuana has been shown to be an effective treatment for pain that may also reduce the chance of opioid dependence,” said New York State Health Commissioner Dr. Howard Zucker. “Adding opioid replacement as a qualifying condition for medical marijuana offers providers another treatment option, which is a critical step in combatting the deadly opioid epidemic affecting people across the state.”

Opioid replacement joins the following 12 qualifying conditions under the state’s Medical Marijuana Program: cancer; HIV infection or AIDS; amyotrophic lateral sclerosis (ALS); Parkinson’s disease; multiple sclerosis; spinal cord injury with spasticity; epilepsy; inflammatory bowel disease; neuropathy; Huntington’s disease; post-traumatic stress disorder; and chronic pain.

These emergency regulations went into effect on a temporary basis on July 12, 2018. The Department also filed a Notice of Proposed Rulemaking on July 12, 2018, commencing the process of permanently adopting the regulations. The permanent regulations will be published in the New York StateRegister on August 1, 2018, and will be subject to a 60-day public comment period.

In addition, within the next week, certified patients and designated caregivers will be able to print temporary registry ID cards. This will allow them to purchase medical marijuana products more quickly after registering for the program. Patients may use the temporary registry ID card in conjunction with a government issued photo identification to purchase medical marijuana products from a registered organization’s dispensing facility. Prior to this enhancement to the Medical Marijuana Data Management System, it could take 7 to 10 days for patients and their caregivers to receive their registry identification cards after their registration was approved.

Other recent enhancements to New York’s Medical Marijuana Program include adopting new regulations to improve the program for patients, practitioners and registered organizations; authorizing five additional registered organizations to manufacture and dispense medical marijuana; adding chronic pain and PTSD as qualifying conditions; permitting home delivery; and empowering nurse practitioners and physician assistants to certify patients.

As of July 10, 2018, there are 62,256 certified patients and 1,735 registered practitioners participating in the program.

New York’s Proposed Expansion Of Medical Marijuana Regulations

By Joshua S. Bauchner and Anthony J. D’Artiglio

NEW  YORK: On August 10, 2017 the New York State Department of Health announced a bevy of proposed new regulations and changes to existing regulations designed to update New York’s medical marijuana program.  These new regulations are part of the State’s continued efforts to expand and modernize its medical marijuana program following the addition of chronic pain as a covered illness earlier this year.  This article details the proposed regulations and their impact on the medical marijuana landscape.

Expanded Marijuana Products

Under the current regulations, the dispensable forms of marijuana are severely restricted.  However, the proposed amendments to Section 1004.11(g) greatly expand the marijuana products which can be administered by dispensaries, to now include:  capsules, chewable and effervescent tablets, lozenges, topical forms, transdermal patches and metered ground plant preparations.  Notably, although ground plant preparations are now allowed, the proposed additions to Section 1004.11(g) include a statement that “[s]moking is not an approved route of administration.”

Although not an expansion on the sale of marijuana products, proposed regulation Section 1004.12(b) permits the sale of items which “promote health and well-being” although are not marijuana products.”  Although, what constitutes approved health and well-being products is not yet defined within the proposed regulations, the focus is plainly in line with the treatment of cannabis as a medicine to promote healthy living.  Additionally, this proposal will allow dispensaries to expand their offerings beyond “marihuana products and related products” lending further legitimacy to the enterprise.

Open Dispensary Facilities

The proposed regulations greatly expand access to dispensary facilities to incorporate prospective patients and practitioners.  Specifically, Section 1004.12(f) is to be amended to loosen the restrictions on access to facilities, although Section 1004.12(i) does place the onus on registered organizations to maintain a detailed visitor log of all non-employees accessing the facility.  These critical changes will allow prospective patients and practitioners prior access to facilities thereby allowing patients to better assess the potential for marijuana as a treatment option.

Practitioner Rules

The proposed regulations relax the requirements for practitioners who seek to prescribe medical marijuana to qualifying patients, as Section 1004.1(a)(3) would now allow those practitioners to complete a two hour course before issuing certifications.  Under the old rules, practitioners were required to complete four hour course, thus placing more onerous restrictions on qualified health care providers seeking to enter the field.

Advertising

Although registered organizations still face restrictions on advertising, Section 1004.16(m) of the proposed regulations explicitly permits dispensaries to educate “practitioners about the approved medical marihuana products offered by the registered organization.”  Furthermore, the proposed regulations loosen the restrictions in Section 1004.16(i), which only require registered organizations to submit advertisements to the Department of Health for approval if the advertisement “makes any claims or statements regarding efficacy.”

Miscellaneous Regulations 

Despite relaxing certain regulations to expand the program, there are a number of new, proposed regulations focused on ensuring facility operator compliance.  Notably, Section 1004.12(a) has been amended to require that the onsite licensed pharmacist at each facility must also complete “a four-hour course,” thus ensuring that the relaxed two-hour course requirement in the proposed regulations are inapplicable to the onsite pharmacist.

In that same vein, proposed regulation Section 1004.12(d) places an additional burden on dispensaries to “ensure the prescription monitoring program registry is consulted” prior to all marijuana sale transactions.

The new proposed regulations also add a new testing requirement pursuant to Section 1004.14(h) which now provides for stability testing on each brand and form of medical marijuana products.

Furthermore, New York proposes to add regulations addressing the disposal of medical marijuana under new Section 1004.24, which requires, among other things, that all organizations obtain approval from the Department of Health for disposal methods and that all organizations create and maintain detailed records of all marijuana disposals which are subject to Department of Health review.

Although New York is moving towards a less restrictive medical marijuana environment, individuals and businesses which operate within the cannabis sphere must be mindful of the exacting and frequently changing regulations.  Experienced legal counsel such as Ansell, Grimm & Aaron, P.C. can assist with ensuring compliance with all government regulations in this ever-changing and rapidly expanding marketplace.


For more information, please visit us at ansellgrimm.com, follow us @THCCounselors, and contact us at (973) 247-9000.

First Medical Marijuana Dispensaries In New York Open

NEW YORK: New York joined the ranks of nearly half the states on Thursday in allowing the use of medical marijuana with the opening of eight dispensaries statewide, serving a variety of tinctures, concentrates, vapors and other forms of the drug.

How many patients actually received medicine from those dispensaries, however, was uncertain; several locations around the state had customers who entered, but it was not clear if any actually bought the drug, or were qualified to do so under the state’s strict guidelines. On Thursday, officials at the state’s Department of Health said that only 51 patients had been certified for the program thus far, though that process only began on Dec. 23 and requires the approval of a physician who has registered with the state.

Want To Sell Medical Marijuana In New York? It Could Cost You $30 Million

NEW YORK: In business, you have to spend money to make money. In the New York medical marijuana industry, you may just be spending money.

Medical marijuana was legalized in New York in July 2014; however, the licenses to sell were just announced July 31 of this year. Applicants had to pay a refundable registration fee of $200,000 along with a non-refundable $10,000 fee. For a comparison, in Oregon, the application fee is $4,000 and in Massachusetts, there is a Stage One application fee of $1,500 and a Stage Two application fee of $30,000.

Of the 43 businesses that applied, five companies — Bloomfield Industries, Columbia Care NY, Empire State Health Solutions, Etain and PharmaCann — were awarded licenses. Of the states that have legalized marijuana, some — like Florida and Minnesota — also restrict the number of license holders, while others, such as Colorado and California, grant much greater access to licensees.